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Abstract: Decades of chemical, biochemical and patho-
physiological research have established the relevance 
of post-translational protein modifications induced by 
processes related to oxidative stress, with critical reflec-
tions on cellular signal transduction pathways. A great 
deal of the so-called ‘redox regulation’ of cell function is 
in fact mediated through reactions promoted by reactive 
oxygen and nitrogen species on more or less specific ami-
noacid residues in proteins, at various levels within the 
cell machinery. Modifications involving cysteine residues 
have received most attention, due to the critical roles they 
play in determining the structure/function correlates in 
proteins. The peculiar reactivity of these residues results 
in two major classes of modifications, with incorpora-
tion of NO moieties (S-nitrosation, leading to formation 
of protein S-nitrosothiols) or binding of low molecular 
weight thiols (S-thionylation, i.e. in particular S-glutath-
ionylation, S-cysteinylglycinylation and S-cysteinylation). 
A wide array of proteins have been thus analyzed in detail 
as far as their susceptibility to either modification or both, 
and the resulting functional changes have been described 
in a number of experimental settings. The present review 
aims to provide an update of available knowledge in the 
field, with a special focus on the respective (sometimes 
competing and antagonistic) roles played by protein 
S-nitrosations and S-thionylations in biochemical and cel-
lular processes specifically pertaining to pathogenesis of 
cardiovascular diseases.
Keywords: cardiovascular diseases; glutathione; mixed 
disulfides; nitric oxide; RNS; ROS; S-glutathionylation; 
S-nitrosation.
Introduction
The role of nitric oxide (NO) in several signaling routes 
has been clearly established (Grisham et al., 1999; Pacher 
et  al., 2007). NO, one of the most important substances 
produced by the endothelium, plays a key role in home-
ostasis maintenance and has gained recognition as a 
crucial modulator in vascular pathophysiology. NO has 
a number of intracellular effects, e.g. vasorelaxation, 
endothelial regeneration, inhibition of leukocyte chemo-
taxis, and platelet adhesion. The physiological chemistry 
of NO is complex, for it encompasses numerous potential 
reactions. Increasing attention has been paid to its ability 
to produce covalent post-translational protein modifi-
cations, and among these, the modification of cysteine 
residues has received more attention due to the functional 
relevance of many of them. The cysteine thiol may be modi-
fied by incorporation of a NO moiety (S-nitrosation) or of a 
glutathione moiety (S-glutathionylation). Both modifica-
tions may ensue from different reactions induced by nitric 
oxide-related species, especially S-nitrosoglutathione 
(GSNO). GSNO is one of the most important intracellular 
S-nitrosothiols (Martínez-Ruiz and Lamas, 2007), and as 
will be detailed below, a number of studies have investi-
gated its potential use as a therapeutic agent in selected 
conditions, including cardiovascular dideases (Hornyák 
et al., 2011).
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In the present review, the first part will focus on the 
role of NO as a signaling molecule, by analyzing the main 
post-translational modifications (PTMs) it can induce in 
cellular proteins. The second part will explore the simi-
larities, differences and commonalities between the pro-
cesses of protein S-nitrosation and S-glutathionylation. 
In fact, both modifications share many mechanistic and 
functional features, making them solid candidates as 
general mechanisms for intracellular signal transduc-
tion. Finally, the third section will focus on the identifi-
cation of proteins individually modified by S-nitrosation 
and S-gluthathionylation. The most abundant protein 
thiol is the free cysteine of albumin, which makes of this 
abundant protein an inevitable target of both processes. 
S-nitrosylation of albumin has been recognized since the 
beginning as a mechanism involved in the bioactivity of 
endothelium-derived NO, at that time denoted as EDRF 
(Stamler et al., 1992; Keaney et al., 1993). Our review will 
be focused on the resulting effects of these PTMs on other 
protein targets critical in cardiovascular pathophysiology. 
The competition of the two processes on the same protein 
targets will also be discussed, taking into account the dual 
ability of GSNO to both S-nitrosate as well as S-glutathio-
nylate proteins.
NO signaling in the cardiovascular 
system
NO is a gaseous radical with a short half-life, continuously 
synthesized from L-arginine by the nitric oxide synthase 
(NOS) (Palmer et  al., 1988). There are three distinct iso-
forms of NOS that differ in structure and function (Stuehr, 
1997). Endothelial NOS (eNOS) and neuronal NOS (nNOS) 
are constitutively expressed and are referred as Ca2+-
dependent enzymes (Ayajiki et  al., 1996) and generate 
small amounts of NO for signaling. The third type is the 
inducible isoform (iNOS), Ca2+-independent and inducible 
by immunological stimuli (Schulz et al., 1992). This latter 
is activated in response to inflammation and generates 
high amounts of NO (Knowles and Moncada, 1994).
From a functional point of view, NO acts as a chemical 
messenger particularly in vascular and immune systems, 
where it participates in the regulation of a wide range of 
physiological processes. Its production within the cell is 
finely adjusted to ensure appropriate effects. Indeed, in 
physiological conditions, the low concentrations of NO 
(10 nm) produced by eNOS can act both as a vasodilator 
and an inhibitor of platelet aggregation. Through nitros-
ylation, NO released from the endothelium stimulates 
soluble guanylyl cyclase (sGC), producing increased con-
centrations of cyclic guanosine monophosphate (cGMP). 
Cyclic GMP interacts with three types of intracellular pro-
teins: cGMP-dependent protein kinases (PKGs), cGMP-reg-
ulated ion channels, and cGMP-regulated cyclic nucleotide 
phosphodiesterases (PDEs). Thus, cGMP can alter cell 
function through mechanisms dependent or independent 
of protein phosphorylation. Depending on the sites of NO 
release and cGMP activation, different biological effects 
can be observed. In vascular smooth muscle cells (VSMCs), 
increased cyclic GMP concentrations will activate cGMP-
dependent kinases capable of decreasing intracellular 
calcium, thus producing relaxation (Moncada et al., 1991), 
whereas increased cGMP in platelets will decrease platelet 
activation and adhesion to the surface of the endothelium 
(Radomski and Moncada, 1993).
Conversely, the activation of iNOS, induced during 
pathophysiological processes such as inflammation, pro-
duces much higher concentrations of NO (>1 μm). iNOS 
is expressed physiologically, but is induced by certain 
inflammatory cytokines (IL-1, INFγ, TNF-α), LPS and oxi-
dizing agents. The effects of NO will depend on the site of 
its formation, concentrations achieved, as well as the type 
of targeted tissue.
Generally, modulation of protein function by NO can 
occur through three main reactions:
1. Nitrosylation, a reversible coordination of NO to tran-
sition metal ions in enzymes, such as ferrous (Fe2+) 
heme prosthetic groups within the sGC enzyme, lead-
ing to enzyme activation and increased formation of 
cGMP.
2. Protein nitrosation, with formation of a covalent bond 
between NO and cysteine (S-nitrosation) or tryptophan 
(N-nitrosation) residues. Modifications of free cysteine 
residues present at active sites of effector proteins and 
peptides will change the activity or function of these 
proteins. This configures a mode of post-translational 
protein modification as important as phosphorylation 
(Lima, 2010; Heikal, 2011). A number of studies have 
focused on the mechanistic aspects of protein nitro-
sation (see e.g. Wolhuter and Eaton, 2017), however 
it has been shown that de-nitrosation reactions also 
play critical roles in the control of nitrosated proteins 
levels as well as of NO release. In the specific case of 
S-nitrosation, the formed S-nitrosothiols (RSNOs) can 
undergo spontaneous or assisted trans-nitrosations, 
resulting in the transfer of the NO moiety from high 
molecular weight (protein) thiols to low molecular 
ones, and inversely.
3. Nitration, i.e. the addition of a nitro group (NO2) 
covalently bound to the aromatic ring of tyrosine 
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or tryptophan residues. This often results in a loss 
of protein function, due to the involvement of func-
tionally important residues, as well as in proteolytic 
degradation of damaged proteins. Nitration mainly 
consists in the formation of nitrotyrosine, occur-
ring either via peroxynitrite or via the one-electron 
oxidation of nitrite by peroxydases in the context of 
heavy tissue inflammation and oxidative stress (van 
der Vliet et al., 1997; Wu et al., 1999). Nitrotyrosine is 
identified as an indicator or marker of cell damage, 
of inflammation as well as of high NO production. 
Previous studies have demonstrated that nitrotyros-
ine is enriched in human atherosclerotic lesions and 
low-density lipoprotein (LDL) obtained from human 
atheromas (Shishehbor et al., 2003).
Decreased levels of endogenously produced NO have been 
linked to a number of cardiovascular diseases (CVD). 
Decreased NO bioavailability can have different origins, 
e.g. (i) the impairment of endothelial membrane recep-
tors that mediate the release of NO in response to agonists 
or mechanical stimuli, (ii) decreased levels or impaired 
utilization of L-arginine substrate, or cofactors for NOS 
(such as BH4), (iii) decreased concentration or activity of 
NOS, (iv) enhanced degradation of NO by oxygen free radi-
cals, (v) impaired diffusion from endothelium to smooth 
muscle cells (SMCs), (vi) impaired interaction of NO with 
soluble guanylate cyclase and limitation of the increase 
in intracellular cGMP levels, (vii) generalized decrease in 
smooth muscle cell sensitivity to vasodilators (Briasoulis 
et al., 2012). Decreased NO bioactivity is a consequence of 
endothelial dysfunction, and may thus contribute to the 
development of atherosclerosis and its clinical expression 
in several CVD forms (Tousoulis et al., 2012).
Conversely, excess NO produced during inflam-
mation and oxidative stress has also been repeatedly 
involved at the basis of cardiovascular pathologies. Such 
relationships can be summarized as follows: (i) NO is 
released during inflammation processes (mainly fol-
lowing the activation of inducible NO synthase), (ii) it 
induces positive or negative effects on vascular homeo-
stasis, depending on its concentration and other concur-
rent factors, with deleterious impacts during oxidative 
stress and inflammation, and (iii) the released NO can 
itself modulate the production and action of inflam-
matory mediators. The reasons for such multiplicity of 
effects lie in concentrations, duration of exposure, and 
origin of increased NO: i.e. direct production from NOSs, 
as opposed to release of NO from the endogenous res-
ervoir represented by S-nitrosothiols (RSNOs). The role 
of the latter as an important storage form of NO will be 
discussed below.
A summary of NO effects related to its concentration 
and cardiovascular conditions is reported in Figure 1.
Protein nitration
ONOO–·NO O2·–
P-Tyr-NO2
Proliferation
Apoptosis
Inflammation
sGC
NO reservoircGMP
SMCs
Vasorelaxation Antiaggregation
>1 µM
≈10 nM
iNOS
eNOS
Endothelium
P-SNOProtein S-nitrosation
+
Figure 1: Pathophysiological effects of protein modifications induced by increasing concentrations of NO in the cardiovascular setting.
sGC, soluble guanylyl cyclase; cGMP, cyclic guanosine monophosphate.
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S-nitrosothiols: post-translational protein 
modifications and nitric oxide donors
The delivery of supplementary NO in the form of NO-donor 
drugs represents an attractive therapeutic option for the 
treatment of cardiovascular diseases as well as other 
pahologies. NO donors, i.e. agents capable to release NO, 
are often complex chemicals such as nitrosamines, organic 
nitrates and metal-NO complexes, but simpler molecules 
such as S-nitrosothiols have recently come center stage. 
Over time, several comprehensive reviews have appeared 
in the literature to which the reader is addressed for more 
details (see e.g. Feelisch and Stamler, 1996; Wang et al., 
2002). Basically, three NO release mechanisms were pro-
posed, depending on the chemical structure of the spe-
cific NO donor. The first type is spontaneous NO donation, 
which releases NO through thermal or photochemical 
self-decomposition (e.g. S-nitrosothiols, N-diazenium-
diolates, oximes). The second type is a chemically catal-
ized NO release triggered by acid, alkali, metals and thiols. 
This is the case for organic nitrates, nitrites, sydnonimines 
and S-nitrosothiols. The third type is an enzymatically cat-
alized NO donation depending on enzymatic oxidation or 
reduction: e.g. N-hydroxyguanidines, following the action 
of NOS’s or oxidases, or S-nitrosothiols, following the 
action of redoxins (Perrin-Sarrado et al., 2016). Peptidases 
are also implicated in NO release from S-nitrosothiols, as 
shown by γ-glutamyltransferase (GGT) implication in NO 
release from GSNO, thus mediating its rapid vasorelaxant 
effects (Dahboul et al., 2012).
Some NO-donor drugs are already in widespread clin-
ical use, in particular organic nitrates (e.g. nitroglycerin, 
isosorbide dinitrate or isosorbide-5-mononitrate), organic 
nitrites (e.g. amyl nitrite), the ferrous nitro-complexes 
(e.g. sodium nitroprusside) and the sydnonimines (e.g. 
molsidomine) (Tullett and Rees, 1999).
Conversely, Stamler and co-workers post ulated the 
existence of an endogenous NO reserve in the plasma, 
where NO is in equilibrium with S-nitrosoproteins and/
or S-nitrosopeptides characterized by a covalent S-NO 
bond and serving in NO transport, signal transduction 
pathways and regulation of gene expression (Stamler 
et al., 1992; Stamler, 1994). Indeed, part of the action of 
the endothelium-derived relaxing factor (EDRF) was sug-
gested to be effected through a protein-SNO adduct with 
serum albumin (Keaney et al., 1993).
The formation of S-nitrosothiols may also play an 
important role in leukocyte adhesion to microvascular 
endothelium. S-nitrosothiols are in fact known to inhibit 
leukocyte adhesion to microvascular endothelial cells 
in  vivo, presumably via the release of NO. Sulfhydryl 
groups are essential for normal leukocyte-endothelial 
cell adhesion (Grisham et al., 1998). S-nitrosation of these 
critical -SH groups on the surface of endothelial cells and/
or neutrophils could therefore decrease adhesion, thereby 
limiting leukocyte infiltration. Furthermore, the formation 
of endogenous antiadhesive S-nitrosothiols may be inhib-
ited by O2˙− due to formation of peroxynitrite, suggest-
ing that enhanced O2˙− production during inflammation 
may promote the adhesion of neutrophils to endothe-
lium (Wink et al., 1997). Indeed it is well established that 
exogenous NO donors are very effective at inhibiting the 
adhesion of neutrophils in vivo (Granger and Kubes, 1996; 
Grisham et al., 1998).
In contrast to classic NO donors used in pharmaco-
therapy, S-nitrosothiols could be promising substitutes 
as they do not induce the development of tolerance or 
cyanide poisoning (Al-Sa’doni and Ferro, 2000; Belcastro 
et  al., 2017). S-nitrosothiols proved effective in a variety 
of cardiovascular disorders, including e.g. myocardial 
infarction (Lima et  al., 2009). Alterations of NO homeo-
stasis are implicated in atherosclerosis and the potential 
therapeutic benefit of NO donors (e.g. organic nitrates, 
nicorandil and sydnonimines) or drugs increasing the 
availability of endogenous NO (e.g. statins, angiotensin-
converting enzyme inhibitors, L-arginine and tetrahydro-
biopterin) has been proposed (Gori et  al., 2001; Herman 
and Moncada, 2005; De Meyer et al., 2012). The rationale 
for this implication lies in the potential effects of NO on 
macrophages, SMCs and endothelium, the main cellu-
lar components of atherosclerotic plaque. However, it 
should also be considered that NO by itself (Chang et al., 
1994; Wang et al., 1994) or in combination with superox-
ide anions (Darley-Usmar et al., 1992) can also stimulate 
the oxidation of LDL, which constitutes a critical trigger-
ing event in atherogenesis and makes the picture more 
complex.
Endothelium and SMCs are two critical components 
in  the pathogenesis of atherosclerotic plaques, forming 
the basis for a number of cardiovascular diseases. The 
effects of S-nitrosothiols in normal endothelial cells and 
SMCs were first analyzed by comparing the effects on 
native LDL oxidation of S-nitroso-N-acetyl-penicillamine 
(SNAP), a RSNO, and two other known NO donors, SIN-1 
and sodium nitroprusside (Jaworski et  al., 2001). These 
authors demonstrated that sodium nitroprusside strongly 
oxidizes LDL in medium alone, as well as in endothe-
lial or smooth muscle cell cultures, and it should there-
fore be used carefully in therapy for vascular conditions, 
especially in case of high concentrations and prolonged 
administration. SIN-1 also oxidized LDL in the absence of 
cells, and clearly enhanced the LDL oxidation in cultures 
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(Darley-Usmar et  al., 1992; Mital et  al., 1999). At vari-
ance, SNAP was not able to oxidize LDL either in acellu-
lar systems or in the presence of cells, showing that the 
amount of super oxide and other reactive oxygen species 
released by these cells did not suffice, contrary to those 
liberated by macrophages, to combine with NO and 
produce prooxidant effects. Conversely, it has been shown 
that other S-nitrosothiols such as GSNO could protect 
endothelial cells from the toxic effect of oxidized LDL 
(Struck et al., 1995). In addition, SNAP was reported to be 
useful in the treatment of heart failure, by reducing myo-
cardial oxygen consumption (Mital et al., 1999), inducing 
vasodilation in rat femoral arteries (Megson et al., 1997) 
and inhibiting platelet activation and aggregation (Salas 
et  al., 1994; Gordge et  al., 1998). Taken together, these 
observations suggest that S-nitrosothiols could limit the 
progression of atherogenesis without increasing oxidative 
stress, and thus encourage the pharmacological applica-
tion of these compounds.
S-Nitrosoglutathione (GSNO): the main 
endogenous NO donor
Among endogenous RSNOs, the attention has been mainly 
focused on S-nitrosoglutathione (GSNO) and S-nitroso-
cysteine (Cys-NO), the most represented low-molecular 
weight (lmw) S-nitrosothiols in vivo, because of their 
potential pharmacological and therapeutic applications.
GSNO, formed by the S-nitrosation of reduced glu-
tathione, is the main lmw form for storage and transport of 
NO. It exhibits higher stability than NO, mediates protein 
S-nitrosation processes and is thought to play an impor-
tant role in vascular signaling and protection, especially 
in a context of inflammation (Khan et al., 2006). The bio-
logical activity of GSNO and particularly its vasorelaxant 
effect have been reported in ex vivo isolated vessel models 
(Sogo et  al., 2000; Alencar et  al., 2003; Dahboul et  al., 
2012; Perrin-Sarrado et  al., 2016), and is directly linked 
to its decomposition resulting in the release of NO. Gen-
erally, RSNOs are quite stable in vitro at 37°C and pH 7.4 
(McAninly et al., 1993) but are degraded in vivo, especially 
by enzymatic activities. Indeed, GSNO decomposition 
in  vitro is promoted by factors such as pH, temperature 
and metal ions, while in vivo it is effected by enzyme activ-
ities such as GSNO reductase (GSNOR), carbonyl reduc-
tase 1 (CR1), protein dislfide isomerase (PDI), thioredoxin 
system (Trxs) and γ-glutamyltransferase (GGT). Cellular 
mechanisms of GSNO degradation are widely described in 
the literature (Broniowska et al., 2013; Corti et al., 2014), 
and are summarized in Table 1.
In view of its primary relevance as endogenous RSNO, 
as well as of the interest it has raised as potential thera-
peutic agent in cardiovascular diseases and other condi-
tions, GSNO will represent the main focus of this review. 
Cellular responses to GSNO have in fact received great 
attention during the last few years (Broniowska et  al., 
2013). Indeed, GSNO does not induce any tolerance or oxi-
dative stress (Al-Sa’doni and Ferro, 2000;  Belcastro et al., 
2017). To date, there have been nearly 20 clinical trials 
investigating the therapeutic efficacy of GSNO in multi-
ple pathological contexts, and most of them have focused 
on its effects in cardiovascular diseases (Gaucher et  al., 
2013). The best-characterized effects of GSNO in humans 
are its direct and selective actions on platelets (Langford 
et al., 1994; Kaposzta et al., 2002). GSNO has been shown 
to decrease embolism from symptomatic carotid plaques 
and after carotid endarterectomy or angioplasty (Kaposzta 
et  al., 2002) or vein graft (Salas et  al., 1998) by limiting 
platelet activation. Its beneficial effects in the vasculature 
extend to cardiac left ventricular function and systemic 
vasodilation (Rassaf et al., 2002), and preeclampsia (Lees 
et al., 1996) (Table 1). Although with some discrepancies 
related to the analytical method used (Giustarini et  al., 
2006; Bramanti et  al., 2009), GSNO was found at nano- 
to low micromolar concentrations in extracellular fluids 
and tissues (Gaston et  al., 1993; Kluge et  al., 1997; Gius-
tarini et al., 2006), and due to its nature of endogenous 
compound and its important role in NO signaling and 
S-nitrosation, it has been considered an attractive can-
didate for therapeutic applications (Snyder et  al., 2002; 
Corti et  al., 2014). However, despite its powerful anti-
platelet activity, vasodilator effects, antimicrobial and 
antithrombotic effects, this molecule is not yet present 
in any pharmaceutical composition for the treatment of 
vascular diseases. Considering that its stability is limited 
by enzymatic and non-enzymatic degradations, and 
therefore is too low to provide a long-lasting effect and 
to deliver appropriate NO concentrations to target tissues 
for clinical application, GSNO (like RSNOs in general) 
has to be protected. GSNO encapsulation is an interest-
ing response to provide protection from degradation, 
but its hydrophilic nature and the instability of the S-NO 
bond during the formulation process raise difficulties for 
encapsulation. The direct encapsulation of GSNO within 
polymeric nanoparticles and nanocomposite particles has 
been recently described, with preservation of the activ-
ity of this fragile molecule after the formulation process 
(Wu et al., 2015a,b). As far as protection against degrada-
tion effected by γ-glutamyltransferase, useful hints could 
derive from previous studies on glutathione. In in vitro 
experiments, it was in fact shown that complexation of 
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GSH with α-cyclodextrin (α-CyD) could afford 50% pro-
tection against GGT at 2 h (Garcia-Fuentes et al., 2006).
These formulations for chronic oral treatments with 
GSNO showed a sustained in vitro release of GSNO (Wu 
et  al., 2015b) and a storage of NO in the vascular wall 
17  h after oral administration to wistar rats (Wu et  al., 
2016). Other formulations developed for subcutane-
ous long lasting delivery of GSNO also showed poten-
tial for stroke treatment (Parent et al., 2015). Even if the 
potential of GSNO for NO supplementation is limited by 
its poor stability and high hydrophilicity, causing NO 
release to not be sustained long enough for a chronic 
in vivo therapeutic effect, these studies however repre-
sent a starting point for the implementation of chronic 
oral treatments with GSNO, e.g. for the treatment of vas-
cular diseases.
S-Nitrosation vs. S-glutathionylation: 
differences, similarities and 
commonalities
NO can affect cardiovascular physiology in different 
ways. In addition to the classic NO-mediated activation of 
the cGMP-dependent pathway, in recent years increasing 
attention has been paid to the ability of NO to produce 
covalent post-translational protein modifications, in con-
junction with other reactive oxygen (ROS) and nitrogen 
species (RNS). Among these, the modification of cysteine 
residues has been shown to be of particular importance 
due to the functional relevance of many of them. In this 
second part we are focussing on the modification of 
the cysteine thiol by the incorporation of a NO moiety 
(S-nitrosation) or the formation of a mixed disulfide 
between a protein thiol and a lmw thiol (S-thionylation). 
Levels of glutathione (GSH) are remarkably high at intra-
cellular level, and S-glutathionylation, the reversible 
addition of glutathione to thionylate anions of cysteines 
in target proteins, is the most abundant type of thionyla-
tion, and likely the most important (Chai et  al., 1994a; 
 Ravichandran et  al., 1994; Schuppe-Koistinen et  al., 
1994).
Both S-nitrosation and S-thiolation can indeed result 
from the action of nitric oxide-related species. Conversely, 
as the intrinsic instability of the nitrosothiol bond facili-
tates its rapid reaction with other species to generate 
more stable disulfide bonds, it has been suggested that 
protein (mixed) disulfides formed in this way, via a nitro-
sothiol intermediate redox state, likely represent the end 
modifications actually mediating functional alterations 
in target proteins (Wolhuter and Eaton, 2017). There are 
emerging data suggesting that both PTMs play an impor-
tant role in cardioprotection, for they not only lead to 
changes in protein structure and function but also protect 
these thiol(s) from further irreversible  oxidative/nitrosa-
tive modification. A better understanding of these mecha-
nisms and their roles is needed, in view of new therapeutic 
opportunities and targets for interventions in cardiovas-
cular diseases.
The perturbation of thiol-disulfide homeostasis is a 
critical process in many diseases. The reduced/oxidized 
glutathione (GSH/GSSG) redox couple is of great impor-
tance in maintaining cellular redox status, including 
modulation of protein thiols. The estimated in vivo redox 
potential for the GSH/GSSG couple ranges from −260 mV to 
−150 mV depending on the conditions (Jones, 2002). Thus, 
changes in the GSH/GSSG ratio are fundamental in the fine 
tuning of signal transduction related, for example, to cell 
cycle regulation (Schafer and Buettner, 2001). Under oxi-
dative stress, the concentration of GSH decreases leading 
to irreversible cell degeneration and death. In fact, shift-
ing the GSH/GSSG redox toward the oxidizing state acti-
vates several signaling pathways including protein kinase 
B, calcineurin, NF-κB, c-Jun N-terminal kinase, apoptosis 
signal-regulated kinase 1, and mitogen-activated protein 
kinase, thereby reducing cell proliferation and increasing 
apoptosis (Sen, 2000). In recent years, additional roles of 
GSH related to signal transduction have emerged.
The most common covalent protein PTMs of cysteine 
residues are those involving NO, i.e. S-nitrosation, or 
a thiol, by incorporation for example of a glutathione 
moiety, S-glutathionylation (Figure 2).
S-Nitrosation is a redox-dependent, thiol-based, 
reversible post-translational protein modification (Gow 
et al., 2002; Gaston et al., 2006; Paige et al., 2008; Foster 
et  al., 2009) and it is analogous to phosphorylation, 
S-glutathionylation, palmitoylation, acetylation and other 
physiological modifications of proteins. When compared 
to other signaling mechanisms such as phosphorylation, 
it presents unique features, e.g. the fact that S-nitros-
othiols can be also formed and degraded depending on 
spontaneous chemical reactions without the aid of enzy-
matic catalysis. Thus, some concepts like specificity are 
based on different biochemical principles, and hence this 
may represent a new paradigm in signal transduction 
( Martínez-Ruiz and Lamas, 2004).
Conversely, S-glutathionylation provides protection 
of protein cysteines from irreversible oxidation and serves 
to transduce a redox signal by changing structure/func-
tion of the target protein (Ghezzi, 2005, 2013). This process 
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is observed both under physiological redox signaling or 
oxidative stress. Protein S-glutathionylation involves the 
reaction of protein cysteine residue, or an oxidized deriva-
tive such as S-nitrosyl (S-NO), sulfenic acid (S-OH), thiyl 
radical (S˙), with GSH. The reversal of S-glutathionylation 
(i.e. de-glutathionylation) is catalyzed by glutaredoxin 
(Grx) at the expense of GSH as a cosubstrate (Kalinina 
et al., 2014).
The PTMs described above can alter protein func-
tion, by regulating the activities of several redox-sensitive 
Figure 2: Chemical pathways leading to the formation of protein S-nitrosation and S-glutathionylation.
The thiol group in side chain of a cysteine residue is susceptible to several oxidative modifications. Its oxidation can result in the forma-
tion of a cysteinyl radical (P–S, not shown) or a sulfenic (PSOH) (A), sulfinic (PSO2H) (B) or sulfonic (PSO3H) acid (C). The formation of PSOH 
can be reversed, for example by GSH, while the two other species are usually irreversible. Alternatively, oxidation can result in the forma-
tion of disulfide bridges (D, D′). Disulfides can form between two adjacent proteins (intermolecular cystine, or interprotein disulfide) (D) or 
between two adjacent sulphydryl groups within the same protein (intramolecular cystine, or intraprotein disulfide) (D′), causing changes in 
protein aggregation and conformation. Reaction between protein -SH grous and lmw. thiols such as GSH and free cysteine can yield protein-
glutathione (E), protein-cysteine (F) or protein-cysteinylglycine mixed disulfides (G), respectively (i.e. S-glutathionylated, S-cysteinylated 
or S-cysteinylglycinylated proteins). Protein thiols found in consensus motifs wherein the cysteine is adjacent to basic and acid residues or 
aromatic residues can serve as sites of S-nitrosation, which can be mediated by NO, S-nitrosothiols (i.e. GSNO) or several higher N-oxides 
(H), or catalyzed by transition metals.
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proteins. This has been discussed for both sets of modifi-
cations (Nathan, 2003), although each modification has 
special and unique features. In this regard, S-nitrosation 
shows some parallels with sulfenic acid formation, as it 
is easily reversible (Poole et  al., 2004). Sulfinic and sul-
fonic acid formation are more stable modifications, which 
have been considered as irreversible in cell systems until 
the description of reversion enzymatic mechanisms 
for sulfinic acid (Biteau et  al., 2003; Woo et  al., 2003). 
Disulfide bond formation is a well-known redox modifica-
tion in proteins, largely dependent not only on the redox 
environment but also on protein structure. However, 
S-glutathionylation can be considered as the most impor-
tant thionylation, as it has been also shown to be the most 
abundant (Chai et  al., 1994a; Schuppe-Koistinen et  al., 
1994).
Numerous reports have shown the importance of 
oxidative cysteine modification in proteins in modulat-
ing cardiovascular function, and both protein S-nitros-
ation and S-glutathionylation are emerging as a critical 
signaling mechanism in cardiovascular diseases. Both 
PTMs in fact appear to regulate several physiologi-
cal processes involved in cardiovascular homeostasis, 
including myocyte contraction, oxidative phosphoryla-
tion, protein synthesis, vasodilation, glycolytic meta-
bolism and response to insulin. Thus, perturbations in 
protein nitrosation/glutathionylation status may con-
tribute to the etiology of many cardiovascular diseases, 
such as myocardial infarction, cardiac hypertrophy and 
atherosclerosis.
There are several chemical mechanisms that can lead 
to both S-nitrosation and S-glutathionylation in protein- 
cysteine thiols. First, it is necessary to assume that the 
formation of both modifications does not occur directly by 
addition of the species, nitric oxide (·NO) or glutathione 
(GSH), to the cysteine thiol (P–SH), but a redox reac-
tion is needed by losing one electron per sulfur atom in 
the case of nitrosation, and two electrons in the case of 
S-glutathionylation.
A direct reaction is only possible if a thiyl radical 
is formed on the cysteine thiol (P–S˙), that would easily 
react with nitric oxide (a) or with glutathione thiyl 
radical (b):
 P S NO P S NO− +⋅ → − −i  (a)
 P S GS P S SG− + → − −i i  (b)
Moreover, oxidized species are the most important 
candidates for modifying a reduced thiol, and N2O3, 
the higher oxidation state among nitrogen oxides (c), is 
 considered the S-nitrosating species par excellence (Wink 
et  al., 1993; Hogg, 2002). Oxidized glutathione (GSSG) 
would be the equivalent for glutathione (d):
 2 3 2N O RSH RSNO H NO
+ −+ → + +  (c)
 P SH GS SG P S SG GSH− + − → − − +  (d)
Another mechanism, sharing some common fea-
tures, is the transfer of the modification between two 
distinct thiols. In the case of S-nitrosation, this is termed 
transnitrosation (e), a fast reaction likely to occur quite 
easily in cells (Rossi et  al., 1997; Liu et  al., 1998). The 
disulfide exchange between glutathione and another thiol 
(including S–glutathionylation by GSSG) could be called 
‘transglutathionylation’ (f), and is a slow, thermodynami-
cally unfavored reaction basing on typical redox poten-
tials for cysteine residues (Gilbert, 1995):
 R SH R NO R NO R SHS S− + − − → − − + −′ ′  (e)
 R SH R SG R SG R SHS S− + − − → − − + −′ ′  (f)
Transnitrosations are likely to occur promptly, but can 
be easily reverted by other thiols, a circumstance that may 
explain in part the high lability of protein S-nitrosation. In 
contrast, S-glutathionylation by GSSG is less likely if not 
assisted by enzymes, such as those described below, but 
may become more stable in the presence of other thiols, 
e.g. glutathione itself.
An alternative mechanism for protein mixed disulfide 
formation derives from the intriguing observation that 
this modification may occur in intact cells in various 
experimental models of ROS generation, even without 
any detectable changes in the GSH/GSSG ratio (Chai et al., 
1994a,b). This has been explained by direct oxidation of 
protein cysteines by ROS generating a reactive protein 
thiol intermediate such as a thiyl radical or sulfenic acid 
(g), which further reacts with GSH to form the mixed 
disulfide (h) (Poole et al., 2004):
 − + → − +2 2 2P SH H O P SOH H O  (g)
 2P SOH GSH P S SG H O− + → − − +  (h)
In support of this hypothesis, it was demonstrated 
that the active-site CyS-215 of protein tyrosine phosphatase 
(PTP-1B) can be oxidized by superoxide and H2O2 to a 
short-lived sulfenate (Denu and Tanner, 1998; Lee et al., 
1998), which is rapidly converted into the relatively more 
stable mixed disulfide by GSH (Barrett et  al., 1999a,b), 
preventing it from being overoxidized. These findings are 
important for interpretation of previous work (reviewed in 
Claiborne et  al., 1999) proposing that protein sulfenates 
may represent a stable and functionally relevant oxidized 
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form of a protein thiol. However, although there is evi-
dence that some protein sulfenates may be stable oxida-
tion end products when they are stabilized and protected 
against reaction with other thiols by the protein structure, 
the possibility should be considered that sulfenates can 
only survive in unnatural oxidizing conditions in vitro, 
i.e. in experiments carried out in the absence of GSH 
( Claiborne et al., 1993).
Finally, an emerging concept suggests that S-nitro-
sation could be considered as an intermediate step to 
S-glutathionylation (Wolhuter and Eaton, 2017). Indeed, 
the S-nitrosothiol itself represents another activated form 
of the protein cysteine thiol, and can react with GSH 
leading to S-glutathionylation (i):
 − = + → − +PS N O GSH PS SG HNO  (i)
which is chemically equivalent to the S-glutathionylation 
produced by GSNO (j):
 + → − +PSH GSNO PS SG HNO  (j)
Individual analysis of each single mechanism is very dif-
ficult, especially if we consider the fast transnitrosation 
reaction between the two types of nitrosothiols (k):
 + +PSNO GSH  PSH GSNO  (k)
Thus, the role of S-nitrosothiols as primers for S-glutath-
ionylation should be considered as a whole, with special 
emphasis given to GSNO as a reagent that can induce not 
only S-nitrosation but also S-glutathionylation in proteins.
Although S-nitrosation and S-glutathionylation in cells 
can be explained by mere chemical reactions, some enzy-
matic systems have been described as capable of acceler-
ating some of the steps involved. Regarding S-nitrosation, 
and apart from the fact that certain protein targets are spe-
cifically assisted in their modification (Hess et al., 2005), 
the main enzymatic mechanism described so far is the one 
assisted by GSNOR activity. The latter is otherwise known 
as the GSH-dependent formaldehyde dehydrogenase activ-
ity (Jensen et al., 1998) and would presumably have a func-
tion in controlling the levels of intracellular GSNO (and, 
indirectly, of protein S-nitrosothiols as well) as it promotes 
the formation of GSNHOH, a non-NO donating molecule.
Although GSNOR is the most ubiquitous and well- 
studied enzyme in GSNO metabolism, other enzymes 
are also involved, such as plasma membrane 
γ-glutamyltransferase (GGT). GGT is able to hydrolize GSNO 
to the less-stable dipeptide S-nitroso-cysteinylglycine 
(CGSNO), which rapidly releases NO in presence of trace 
metal ions (Hogg et al., 1997; Angeli et al., 2009). Although 
GGT activity resides on the outer aspect of cell membrane, 
it can be envisaged that, by cleaving extracellular GSNO, 
GGT may facilitate SNO uptake and S-nitrosation of intra-
cellular proteins (Hogg et al., 1997; Zhang and Hogg, 2005). 
In this regard for instance, it was demonstrated that GSNO-
induced Akt kinase activity and the subsequent down-
stream  HIF-1α  stabilization are blocked by acivicin, a GGT 
inhibitor (Carver et al., 2007). Many studies have provided 
evidence in favor of a crucial role of plasma membrane-
bound GGT enzymatic activity in the modulation of the 
redox status of cellular protein thiols, with special refer-
ence to proteins of the cell surface. Dominici et al. found 
that GGT activity is associated with the transient loss of 
free protein thiols on the surface of U937 lymphoma cells 
(Dominici et al., 1999), suggesting that this occurs through 
GGT-dependent S-glutathionylation. The mechanism by 
which GGT induces protein thionylation may involve H2O2 
and reactive thiol metabolites (thiyl radicals), both gener-
ated as by-products of GGT mediated GSH metabolism. It 
was in fact shown that reactive cystinyl-glycine, produced 
during GGT-dependent GSH metabolism, can bind protein 
thiols thus producing a protein S-cysteinyl-glycinylation 
(Corti et al., 2005). In this way the redox status of protein 
thiols can be modulated, with potential reflections on cell 
proliferation as well as on the resistance against drugs 
such as chemoterapeutics (Corti et al., 2010). Interestingly, 
GGT expression levels vary considerably among cells types 
(Hanigan and Frierson, 1996; Pompella et  al., 2006) and 
may increase upon cell activation (Khalaf and Hayhoe, 
1987; Corti et al., 2010).
Other important enzymes involved in this context and 
their corresponding mechanisms of action are described 
in Table 2.
As far as disulfide exchange with S-thionylation, this 
is a slow chemical reaction that is accelerated in the intra-
cellular environment by several enzyme activities helping 
to maintain the reduced state of intracellular thiols 
by transferring the oxidizing equivalents to an accep-
tor cosubstrate. Trx, Grx and PDI have been involved in 
catalyzing the breaking of protein-GSH mixed disulfides 
(Shelton et al., 2005; Biswas et al., 2006). More recently, 
sulfiredoxin, the enzyme that reverts protein sulfinic acid, 
has been shown to potentially play the same role (Findlay 
et al., 2006). In addition, glutathione S-transferase P has 
also been involved in S-glutathionylation (Tew, 2007), and 
a role has been recently described for glutathione trans-
ferase omega-1 (GSTO1-1) (Menon and Board, 2013).
Another important factor affecting S-nitrosation and 
S-glutathionylation is subcellular compartmentation. This 
is specially important due to submolecular and hence 
multimolecular specificites, derived from diffusibility and 
structural features of individual compounds (Nathan, 
2003). Indeed, the probability of the reaction between 
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Table 2: S-nitrosated and/or S-glutathionylated protein targets, as assessed after treatment of cells or purified proteins with nitric oxide, 
GSNO or other RNS.
Protein Stimulus S-Nitrosation S-Glutathionylation References
Hb GSNO, diamide, 
superoxide, GSSG
+ + Klatt et al. (2000)
Creatine kinase GSNO, diamide, 
GSSG
+ + Klatt et al. (2000);
Giustarini et al. (2005)
Alcohol dehydrogenase GSNO, diamide + + Klatt et al. (2000);
Giustarini et al. (2005)
Ryanodine receptor GSNO + + Aracena et al. (2003);
Sun et al. (2006b)
Papain GSNO + + Giustarini et al. (2005)
GAPDH GSNO, diamide, 
superoxide, GSSG
+ + Klatt et al. (2000);
Giustarini et al. (2005);
Mohr et al. (1999);
Tao and English (2004)
Actin GSNO + + Dalle-Donne et al. (2003)
c-Jun GSNO, NO/GSH, 
GSSG
+ + Klatt et al. (1999, 2000)
Caspase-3 GSNO, 
SNAP + GSH
+ + Klatt et al. (2000);
Mitchell and Marletta (2005);
Zech et al. (1999)
H-Ras GSNO, ONOO- + + Ji et al. (1999)
BSA Decomposed 
GSNO (diamide)
+ + Tao and English (2004);
Klatt et al. (2000)
Myosin GSNO + + Buttkus (1971);
Pastore and Piemonte (2013)
p50 GSNO, GSSG + Klatt et al. (2000)
Cathepsin K GSNO + Percival et al. (1999)
Aldose reductase GSNO, GSSG + Chandra et al. (1997); 
Srivastava et al. (2003)
Glycerol phosphate 
dehydrogenase
GSNO, diamide + Klatt et al. (2000)
Glutaredoxin GSNO, diamide + Klatt et al. (2000)
Thioredoxin GSNO, diamide + Klatt et al. (2000)
Carbonic anhydrase GSNO, diamide + Klatt et al. (2000);
Ji et al. (1999)
Glycogen phosphorylase b GSNO, diamide + Klatt et al. (2000);
Ji et al. (1999)
Cu, Zn-SOD GSNO, diamide + Klatt et al. (2000);
Tao and English (2004)
Ca2+-ATPase (SERCA) ONOO− + Viner et al. (1999)
Glutathione reductase GSNO + Becker et al. (1995)
Mitochondrial complex I/IV GSNO + Burwell et al. (2006);
Zhang and Hogg (2005)
Citocrome c oxidase GSNO + Reynaert et al. (2004)
NF-KB GSNO + Reynaert et al. (2004)
Trx GSNO + Haendeler et al. (2002)
HIF-1α GSNO + Marshall et al. (2004);
Reynaert et al. (2004)
Actin, Aortic smooth muscle GSNO + Belcastro et al. (2017)
Myosin light chain RCL-A GSNO + Belcastro et al. (2017)
Transgelin GSNO + Belcastro et al. (2017)
Transgelin-2 GSNO + Belcastro et al. (2017)
Tubulin β-2 chain GSNO + Belcastro et al. (2017)
Filamin-A GSNO + Belcastro et al. (2017)
Pdz and Lim domain protein 5 GSNO + Belcastro et al. (2017)
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certain reactive species and certain proteins will be higher 
if they have the same subcellular localization. In the case 
of S-nitrosation, this has been studied mainly in terms of 
the NOS enzymes, as they are the initial source for NO. 
Undoubtedly, the most important mode of regulation of 
eNOS in endothelial cells is related to its acylation and 
interaction with a significant number of proteins, deter-
mining its topological fate. Acylation and other PTMs of 
eNOS – such as phosphorylation and S-nitrosation – can 
in fact dynamically regulate eNOS activity by altering its 
subcellular localization. Iwakiri et al. (2006) showed that 
 S-nitrosation is preferentially taking place at cell sites 
where transfected eNOS is located, and can alter Golgi traf-
ficking function by altering S-nitrosation sensitive proteins.
Conversely, S-glutathionylation is related to a different 
subcellular localization/distribution of GSH. Early experi-
ments detected an important presence of glutathione in the 
nucleus (Hjelle et al., 1994; Voehringer et al., 1998) while a 
more recent study has highlighted the presence of GSH in 
perinuclear sites including mitochondria, with an irregular 
distribution in nuclear, perinuclear and discrete membrane 
localizations (Söderdahl et al., 2003).
Other factors are involved in modulation of 
 S-nitrosation and S-glutathionylation. The half-life of 
Cys-NO in vitro was shown to be shorter than that of GSNO 
across the entire pH range tested (Kuo et al., 2003). The 
stability of GSNO was higher in basic conditions, while 
mildly acidic pH can favor S-nitrosation of target proteins 
in vitro (Hornyák et al., 2012). S-Nitrosation of cysteamine 
by peroxxynitrite was shown to be maximal at strongly 
acidic pH (Mbiya, 2013). The acid dissociation constant 
(pKa) of protein cysteines involved is critical in facilita-
tion of S-glutathionylation. In carbonic anhydrase, dis-
tinct Cys residues were shown to possess higher or lower 
pKa values, and corresponding S-glutathionylation rates, 
depending on their position with respect to specific adja-
cent aminoacid residues in the polypeptide chain (Kim 
and Levine, 2005).
S-Nitrosation vs. S-glutathionylation 
in the cardiovascular system: a 
matter of competition?
When ROS/RNS levels are modified (increased), changes 
are observed in protein activity, stability, conformation 
and/or ability to interact with other molecules, resulting 
in modulation of cellular function. A significant number 
of clinical disorders or pathophysiological entities have 
been in fact related to redox PTMs, and often the same 
protein targets may be affected by either S-nitrosation or 
S-glutahionylation, depending on several factors. In the 
heart, redox modified proteins include proteins involved 
in calcium handling and contractile function, e.g. calmo-
dulin kinase II, calcium channels, ryanodine receptor, 
sarco/endoplasmatic reticulum calcium ATPase (SERCA) 
and phospholamban (Burgoyne et  al., 2012; Steinberg, 
2013; Tullio et  al., 2013), as well as proteins involved 
in various signaling pathways and/or transcriptional 
activities.
The last section of this review is focused on the 
identification of proteins individually modified by both 
S-nitrosation and S-glutathionylation, and on their status 
in cardiovascular disesases. The competition between 
these two PTMs on the same protein targets will be also 
discussed, keeping in mind the dual ability of GSNO to 
promote both types of modification.
Protein S-nitrosation
S-Nitrosation of proteins plays important roles both in 
normal physiology and in a broad spectrum of human 
diseases. As regards the regulation of vascular tone, the 
balance between angiotensin II (Ang-II) and NO appears 
crucial in the cardiovascular and renal systems, where 
homeostasis is lost when the effects of Ang-II predominate 
over those of NO (Schulman et al., 2006). Pathophysiology 
often correlates with hypo- or hyper-S-nitrosation of spe-
cific protein targets, rather than with a loss of or enhanced 
NOS activity (Foster et al., 2009). Dysregulated S-nitrosa-
tions are usually the result of a modification of NO avail-
ability, in dependence of the specific context in which it is 
released, e.g. in concomitance with reactive oxygen, H2S 
and/or other reactive species (Cortese-Krott et  al., 2017). 
In turn, NO availability results not only from alterations 
of the expression, compartmentation and/or activity of 
NOSs, but also reflects the contribution of denitrosylases, 
including GSNO-metabolizing enzymes such as GSNOR, 
producing the non-bioactive molecule GSNHOH, or GGT, 
producing instead reactive S-nitroso-cysteinylglycine, 
CGNO (Dahboul et  al., 2012). The irreversible oxida-
tion of thiols can prevent physiologic modifications by 
S-nitrosation or S-glutathionylation and thereby interfere 
with normal physiologic signaling (Adachi et al., 2004a). 
However, it has been suggested that nitrosation can also 
protect cells from oxidative stress (Sun et  al., 2006a). 
Protein S-nitrosation not only leads to changes in protein 
structure and function, but may also prevent those thiols 
from further irreversible oxidative/nitrosative modifica-
tion. The direct antioxidant properties of NO itself are well 
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established (Wink et  al., 2001). It is not surprising thus 
that the loss or inhibition of NOS can sometimes enhance 
oxidative stress.
High spatial and temporal specificities have been 
shown to affect protein S-nitrosation and its redox 
reversibility. A determinant governing its specificity is 
in fact provided by the colocalization of NO sources and 
target proteins, and is based at least in part on specific 
protein–protein interactions with NO synthases. In addi-
tion, S-nitrosation dependent signaling is also subject 
to temporal constraints, which depend on the timing 
of formation of NO and other nitrosylating equivalents. 
Many Cys-containing proteins in signal transduction cas-
cades are potential targets, as they can undergo a range 
of ROS- or RNS-dependent oxidative and nitrosative 
modifications. Several and diverse cellular responses 
have been described. S-nitrosation can have antioxidant 
effects by inhibiting NADPH oxidase activity (Selemidis 
et al., 2007), or by promoting the ROS scavenging activ-
ity of thioredoxin-1 via S-nitrosation on Cys-69 residue 
(Haendeler et  al., 2002; Liu et  al., 2004a,b). Indeed, 
endothelial cells subjected to physiological shear stress 
produce NO (Gaucher et  al., 2007; Gaucher-Di Stasio 
et al., 2009) and increase protein S-nitrosation indepen-
dently of cGMP-dependent signaling (Hoffmann et  al., 
2003; Huang et  al., 2009). In contrast, after TNF-α or 
mild oxidized LDL treatment endothelial cells present 
with decreased S-nitrosation (Hoffmann et  al., 2001). 
Early studies demonstrated that the activity of AP-1 [an 
important transcription factor regulating gene expres-
sion in response to a variety of stimuli and involved in 
several cellular processes including differentiation, 
proliferation, and apoptosis (Ameyar et  al., 2003)] was 
altered by S-nitrosation (Marshall et al., 2000) or oxida-
tion of Cys residues (Xanthoudakis et al., 1992). Indeed, 
transcriptional activators NF-κB, AP-1 and p53 all contain 
reactive thiols in their DNA binding regions, whose mod-
ification, e.g. by S-nitrosation, can alter their binding 
to DNA. For example in neuronal development, brain-
derived neurotrophic factor can activate nNOS, with sub-
sequent S-nitrosation of histone deacetylase 2 (HDAC2, 
on cysteines 262 and 274) causing its dissociation from 
chromatin (Nott et al., 2008). This increases histone acet-
ylation, permitting transcription of target genes required 
for regulation of dendritic growth (Nott et  al., 2008). 
Additionally, S-nitrosation and denitrosation of critical 
proteins appear to affect cell cycle regulation and are 
involved in the mitotic process (Marozkina and Gaston, 
2012; Rychter et al., 2016).
A number of protein interactions at nuclear level 
are indeed modulated by S-nitrosation. For example, the 
hypoxia-inducible factor 1-α (HIf1-α) is stabilized by phys-
iological levels of S-nitrosothiols following S-nitrosation 
of von Hippel Lindau protein (VHL, C162), preventing its 
degradation (Pawloski et al., 2001). Then HIf1-α can inter-
act with HIF1-β to bind to hypoxia-responsive elements in 
gene promoter regions, resulting in transcription of genes 
such as vascular endothelial growth factor (VEGF). HIF1-α 
can itself undergo both S-nitrosation (Li et al., 2007) and 
S-glutathionylation (Watanabe et al., 2016), both resulting 
in its direct stabilization.
S-nitrosation also affects NF-κB activity, as it can 
involve both p50 (C 62) and p65 (C 38) subunits, as well 
as IκB kinase, IKK (Marshall et al., 2004; Reynaert et al., 
2004). The net effect of these reactions is generally an 
increased cytosolic NF-κB-IκB interaction, preventing 
nuclear translocation and binding of NF-κB to inflam-
matory gene promoters, with overall anti-inflammatory 
action. As with other cellular effects, however, the under-
standing of the role of S-nitrosation signaling in regula-
tion of gene expression is just beginning.
Altogether, modulation of S-nitrosation can offer, in 
principle, novel therapeutic opportunities in a wide range 
of pathologies, firstly in cardiovascular diseases associ-
ated with oxidative stress. As mentioned above, in a thera-
peutic perspective S-nitrosothiols (GSNO in the first place) 
may represent promising NO-donor molecules, compared 
to other NO-related therapeutics limited by tolerance phe-
nomena and oxidant stress (Al-Sa’doni and Ferro, 2000; 
Hornyák et al., 2011).
Protein S-glutathionylation
Protein S-glutathionylation is emerging as a critical sign-
aling mechanism in cardiovascular diseases, as it regu-
lates several relevant physiological processes such as 
oxidative phosphorylation, protein synthesis, myocyte 
contraction, vasodilation, glycolytic metabolism, and 
response to insulin (Mieyal et al., 2008; Pimentel et al., 
2012). Thus, perturbations in protein S-glutathionylation 
status may contribute to the etiology of cardiovascular 
diseases such as atherosclerosis, cardiac hypertrophy 
and myocardial infarction. Protein S-glutathionylation 
is increased following ischemia-reperfusion (IR), with 
the majority of the S-glutathionylation events occurring 
early in the reperfusion period (Eaton et al., 2002). Glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) was 
identified as a cardiac protein S-glutathionylated during 
IR with loss of enzyme function, suggesting that GAPDH 
S-glutathionylation is likely inhibitory in vivo. The 
effects of this inhibition may be multifold: (i) a block of 
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glycolysis, otherwise characteristic of ischemic injury, (ii) 
an interference with its nuclear translocation, resulting 
in increased apoptosis, or (iii) a homeostatic answer to 
the excess of oxidants generated at reperfusion. Of note, 
GAPDH activity is restored at the end of reperfusion, thus 
suggesting that S-glutathionylation may constitute a tem-
porary protection of catalytic cysteines from irreversible 
oxidation. Additional studies highlighted the S-glutath-
ionylation of actin in a rat model of in vivo IR (Chen and 
Ogut, 2006). Studies on isolated G-actin indicated that its 
S-glutathionylation can delay its rate of polymerization 
and decrease the cooperativity of its binding to tropo-
myosin, suggesting that the phenomenon may contribute 
to the decline in cardiac contractility observed during 
ischemia (Wang et al., 2001a,b).
Other targets of S-glutathionylation are the mito-
chondrial complexes I and II. The latter seems to be 
deglutathionylated during IR (Chen et al., 2007), indicat-
ing that a single oxidative stimulus can affect S-glutath-
ionylation in different directions. The potential critical 
role of Grx in myocardial infarction was highlighted 
through experiments in a mouse model of embryonic 
Grx1 knock-out, suggesting a cardioprotective role for 
Grx isoforms (Malik et al., 2008). S-Glutathionylation of 
the mitochondrial complex I, with associated increased 
superoxide production, would be expected to increase 
cytochrome c release and caspase activation, contribut-
ing to infarct size and cardiac dysfunction (Malik et al., 
2008).
The precise role of S-glutathionylation in the devel-
opment and progression of atherosclerosis is unknown. 
However, conditions existing within atherosclerotic 
plaques (i.e. hypoxia, oxidative stress, oxLDL accum-
lation and inflammation) have been shown to promote 
S-glutathionylation in other contexts (Eaton et al., 2002; 
Wang et al., 2006), and Grx has been reported to asso-
ciate with areas of oxidative stress within the vascula-
ture (Okuda et  al., 2001). Protein S-glutathionylation 
increases in human macrophages exposed to oxLDL, 
a major component of atherosclerotic plaques (Wang 
et al., 2006) and, together with GSH depletion, increased 
S-glutathionylated proteins seem to be implicated in 
oxLDL-induced macrophage death in vitro (Kher and 
Marsh, 2004). The role of specific S-glutathionylated 
proteins in macrophage cell death is not yet deter-
mined, nor is it known whether global protein S-glu-
tathionylation increases in other cells types exposed to 
oxLDL. Patients with atherosclerosis obliterans (ASO) 
exhibit increased S-glutathionylation of serum proteins, 
and a positive correlation between disease progression 
and the level of protein S-glutathionylation was found 
(Nonaka et al., 2007). ApoB100, the major component of 
LDL, was identified as a target for increased S-glutath-
ionylation in ASO, but whether the S-glutathionylated 
apoB-100 represents a disease marker or contributes to 
the pathogenesis of ASO remains an open issue (Nonaka 
et al., 2007).
Another target of S-glutathionylation is the 
sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA), a key 
protein regulating the intracellular storage of Ca2+. SERCA 
glutathionylation represents a physiological, cGMP-
independent mechanism of vessel relaxation, which is 
disrupted during atherosclerosis (Adachi et  al., 2004b). 
Molecular biology and mass spectroscopic analysis sug-
gested that S-glutathionylation of Cys-674  was responsi-
ble for SERCA activation. The irreversible oxidation (i.e. 
sulfonic acid formation) at Cys-674 during atherosclerosis 
prevents its reversible S-glutathionylation, and may thus 
contribute to impaired vasodilation of atherosclerotic 
smooth muscle. Analysis of cysteine modifications in 
 atherosclerotic vs. normal rabbit aortas showed increased 
sulfonate formation, corresponding to decreased S-glu-
tathionylation, as well as reduced NO-induced relaxation 
and Ca2+ reuptake (Adachi et al., 2004b).
Oncoprotein Ras, one of the major regulators in 
growth factor signaling in the vasculature, can also 
undergo S-glutathionylation, which could contribute to 
vascular hypertrophy associated with atherosclerosis 
and hypertension in rat (Adachi et al., 2004a). Indeed, 
treatment in vitro of VSMCs with angiotensin II, known 
to induce vascular hypertrophy, led to S-glutathio-
nylation and activation of Ras, resulting in increased 
phosphorylation of p38 and Akt and increased protein 
synthesis. These effects were dependent upon NADPH 
oxidase activation and ROS formation, and were 
blocked by overexpression of Grx1 or mutation of Ras 
at the site of S-glutathionylation (Cys-118) (Wang et al., 
2001a,b; Landmesser et  al., 2002). S-Glutathionylated 
Ras may contribute to atherosclerosis by mediating the 
response to oxLDL in endothelial cells. Treatment of 
bovine aortic endothelial cells with peroxynitrite led to 
Ras S-glutathionylation and activation of both ERK and 
Akt pathways (Clavreul et al., 2006). Akt is emerging as 
a signaling molecule within the heart and vasculature, 
implicated in various pathological signaling events 
as well as in normal development and homeostasis. 
Deglutathionylation by Grx could participate in regulat-
ing the balance between physiological and pathophysi-
ological Akt activation; overall, a complex relationship 
exists between protein S-glutathionylation, Grx and Akt 
activity within the cardiovascular system (Wang et al., 
2007).
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S-Nitrosation vs. S-glutathionylation: 
competition for the same protein 
targets?
In some proteins, a competition between S-nitrosation 
and S-glutathionylation has been described, and the 
suceptibility to either PTM has been compared. It was thus 
shown that there are sensible differences as regards the 
tendency of a protein to undergo one or the other of such 
modifications (Ji et al., 1999; Mallis et al., 2001; Giustarini 
et al., 2005). GSNO is known for its dual ability to S-nitro-
sate as well as S-glutathionylate proteins. As previously 
described, GSNO-dependent protein S-nitrosation occurs 
through the direct transfer of a nitroso group from GSNO 
or another lmw. S-nitrosothiol to a protein thiol through 
transnitrosation. Despite a plethora of studies examin-
ing the effects of GSNO both in vitro and in vivo, few to 
date have identified the compound that actually effects 
 S-nitrosation of a specific protein thiol, i.e. whether it 
may be GSNO or rather another lmw. S-nitrosothiol, e.g. 
L-Cys-NO. Nevertheless, GSNO is the source of the nitroso 
moiety and a likely intermediate in the protein S-nitrosa-
tion process.
S-nitrosation of specific proteins has been proposed 
to play a role in several disease states. Some proteins are 
S-nitrosated in their native state, and variations of basal 
S-nitrosation may control cellular responses with both 
deleterious or beneficial effects. Loss of S-nitrosation 
(hypo-nitrosation) in natively S-nitrosated proteins has 
been found in association with selected pathologies, and 
the same was reported for hyper-nitrosation of other pro-
teins that are not natively S-nitrosated. Attempts to iden-
tify a so-called S-nitrosoproteome, and the specific role 
for GSNO in the process in vivo, have dealt with comparing 
S-nitrosated proteins from different organs in wild-type 
and NOS-knockout mice. These studies have revealed the 
existence of tissue- and context-specific protein targets of 
S-nitrosation, with conflicting results as to pathophysiol-
ogy. NOS-ko mice were in fact protected from heart failure 
(Lima et al., 2009) and asthma (Que et al., 2005), but suf-
fered from increased mortality in models of septic shock 
(Liu et al., 2004a,b).
In addition to transnitrosation, GSNO can slowly form 
disulfides with protein thiols, resulting in S-glutathionyla-
tion. In acellular systems, selected protein thiols appear 
to have a preference for GSNO-dependent S-thionylation 
over S-nitrosation. For example, bovine serum albumin 
showed extensive S-nitrosation after incubation with both 
SNAP and GSNO, whereas creatine kinase favored S-thio-
nylation when exposed to GSNO, but S-nitrosation when 
exposed instead to SNAP (Konorev et al., 2000). In a ther-
modynamic perspective, it is likely that in these contexts 
disulfide formation is the eventual end-point, as the reac-
tion is actually irreversible (at least in the in vitro setting). 
The preference for S-nitrosation or S-thionylation is likely 
due to tuning of reaction kinetics by the thiol environment 
and, as in the example above, the nature of the initial 
S-nitrosothiol. There is evidence that it is not GSNO per se 
but a product of its degradation, glutathione disulfide-
S-oxide, that actually effects protein S-glutathionylation 
(Li et al., 2001; Tao and English, 2004). This may limit the 
biological relevance of the reaction, as it is not clear if this 
oxide can be formed from GSNO in vivo.
Once ascertained that both modifications are possi-
ble if GSNO is produced in the cell, it will become criti-
cal to discriminate which of the cellular proteins will be 
more easily or more stably modified by one or the other 
PTM. The functional relevance of the modifications can 
also become significantly different depending on the site 
of modification. For example, in transcription factors 
that bear in their DNA binding domain a Cys residue that 
needs to be in the reduced state to allow transcriptional 
activity, both modifications can impair this functional-
ity, as it is the case for c-Jun in AP-1 or p50 in NF-κB (Klatt 
et al., 1999; Marshall and Stamler, 2001). Altogether, these 
PTMs likely represent a general mechanism for transduc-
ing oxidative stress into a repression of gene expression. 
Differences between the two PTMs will gain importance in 
terms of stability or potential reversibility. A few examples 
of protein targets modified by both PTMs, likely in a com-
petitive way, are reported below.
Ryanodine receptor channel (RyR2)
It was established that different reactive thiols are 
present in the RyR2 protein, with preferential selectivity 
for S-nitrosation (Sun et al., 2001) or S-glutathionylation 
(Aracena et al., 2003), each leading to specific functional 
consequences. RyR2 is a large ligand-activated intracellu-
lar Ca2+ release channel located at the endoplasmic and 
sarcoplasmic reticulum (SR). Calcium release through the 
cardiac RyR2 triggers heart muscle contraction, and there-
fore RyR2 plays a crucial role in mediating excitation con-
traction coupling after an action potential. The regulatory 
role of S-glutathionylation is not surprising, considering 
that RyR2 contains 364 cysteines with about 84 of them 
having free thiol groups. Basal S-glutathionylation of 
RyR2 was discovered in microsomal fractions enriched in 
SR vesicles isolated from dog cardiac ventricular muscle 
(Sanchez et  al., 2005). Under physiological conditions, 
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such as tachycardia and exercise, RyR2 S-glutathionyla-
tion increases, and this suggests that cardiac cells utilize 
this redox modification to increase RyR2 activity when 
the functional demand is increased (Sanchez et al., 2008). 
The RyR2 activity is enhanced also in heart failure, which 
likely contributes toward decreasing Ca2+ content in SR 
and inducing the Ca2+ release abnormalities observed in 
heart failure. The physiological sources of ROS responsi-
ble for RyR2 redox modifications are poorly understood. 
With both exercise and tachycardia, the administration of 
the NADPH oxidase (Nox) inhibitor, apocynin, prevented 
RyR2 S-glutathionylation and attenuated Ca2+ release 
from the SR (Donoso et al., 2011). Greater understanding 
of RyR2 redox modulation is necessary to counteract the 
deleterious consequences of its deregulation caused by 
oxidative stress.
However, S-nitrosation of cardiac RyR2  has been 
shown to increase its channel opening probability. Con-
versely, the decreased S-nitrosation of RyR2 in hearts of 
nNOS knock-out mice has been suggested to expose its 
Cys residues to oxidation under oxidative stress, leading 
to Ca2+ leakage from SR and arrhythmogenesis (Gonzalez 
et al., 2007).
The cardiac L-type Ca2+ channel, acting as a RyR2 
 activator, is also a target of S-nitrosation, which is reported 
in the literature to decrease the channel activity in hearts 
under adrenergic stimulation (Sun et al., 2006b), oxidative 
stress during ischemia (i.e. preconditioning) (Sun et  al., 
2007) and atrial fibrillation (Carnes et al., 2007).
Sarco(endo)plasmic reticulum Ca2+ ATPase 
(SERCA)
SERCA, the key protein regulating the intracellular storage 
of Ca2+ as it enhances refilling of Ca2+ in sarcoplasmic 
and endoplasmic reticula, is another common target of 
both PTMs. Two major SERCA2 splice variants have been 
characterized: the muscle-specific isoform, SERCA2a, is 
expressed in the SR of the heart and slow-twitch skeletal 
muscle. SERCA2b is found instead in the ER of most cell 
types, and is considered the housekeeping isoform.
A key finding was the observation that SERCA may 
be modified by different post-translational mechanisms 
in the presence of NO-related species (Viner et al., 1999, 
2000). NO can stimulate calcium uptake in SR, thereby 
decreasing intracellular Ca2+ concentration, facilitating 
the uncoupling of the contractile machinery and favoring 
vasorelaxation (Cohen et al., 1999).
Adachi et  al. showed that NO-dependent S-glutath-
ionylation of SERCA2a (occurring via peroxynitrite and 
therefore dependent on superoxide generation, beyond 
NO and GSH) results in an increased activity (Adachi et al., 
2004b). Similarly, in preconditioned (ischemic) hearts, 
Sun et  al. found that SERCA activity was also increased 
by S-nitrosation (Sun et  al., 2007). Peroxynitrite is able 
to activate SERCA by promoting its S-thionylation in the 
context of arterial relaxation, an effect recapitulated by 
eNOS agonists (Eu et al., 2000). A specific target (CyS-674) 
seems to be present, whose S-thionylation results in the 
suppression of NO-mediated increase of activity. Such 
modification occurs in vivo, and a decrease in its levels due 
to irreversible -SH oxidation was found in a rabbit model 
of atherosclerosis, where SERCA S-glutathionylation in 
abdominal aorta was increased, resulting in decreased 
relaxation (Adachi et al., 2004b). In the heart, stimulation 
of SERCA activity and cardiomyocyte contractility by the 
nitroxyl anion generator, Angeli’s salt, also is accompa-
nied by S-glutathionylation (Lancel et al., 2009).
Overall, these data suggest a potential pathophysi-
ological role of SERCA S-nitrosation and S-glutathionyla-
tion in vascular disease. However, whether S-nitrosation 
of SERCA can increase activity per se, or rather it does so 
by enhancing S-glutathionylation, remains to be clarified.
Oncoprotein Ras
The oncogenic Ras protein may become S-nitrosated, and 
this may convert it to its biologically active GTP-bound state 
(Lander et al., 1997). Heo et al. have contributed to explain 
the structure-functional relationships of Ras S-nitrosation 
in CyS-118, hence gaining mechanistic insight into the 
process of NO-mediated Ras guanine nucleotide dissocia-
tion in the presence of O2 (Heo and Campbell, 2006). Con-
versely, Ras may also undergo S-glutathionylation at the 
same cysteine residue (Ji et al., 1999; Mallis et al., 2001), 
and it was suggested that this modification may mediate 
signaling by Ang-II in vascular SMCs (Adachi et al., 2004a). 
Peroxynitrite, albeit at moderately high concentrations, is 
able to promote S-thionylation of Ras in endothelial cells, 
and this has been correlated with the activation of its 
downstream signaling effectors (Clavreul et al., 2006). Of 
interest, modifications of Ras cysteines (not yet identified) 
in myocites are potentially reversible by Trx (Kuster et al., 
2005). In terms of pathophysiology, one of the most inter-
esting observations situates ROS-induced S-thionylation 
of Ras as a mediator of cardiac myocyte hypertrophy in a 
strain-stimulated model. The modification of Ras likely 
occurs at CyS-118 and consists in a S-nitrosation followed 
by an exchange reaction, leaving Ras S-glutathionylated 
(Pimentel et al., 2006).
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Hemoglobin (Hb)
Hb is a target for S-nitrosation and this modification may 
play a physiological role. NO binds to the most reactive 
thiol in human Hb, Cys-93, which led to hypothesize the 
ability of the resulting S-nitroso-Hb to serve as a storage 
and transport form of NO participating in the control of 
vascular tonus (Jia et  al., 1996). Following this observa-
tion, a number of studies have investigated in detail the 
roles potentially played by S-nitrosohemoglobin, actually 
fueling a long controversy. On the one hand, experimental 
results were confirming the ability of S-nitrosohemoglobin 
to serve as a generator of NO, thus providing a precious 
source of the mediator in the vascular system (Stamler 
et al., 1997; Allen et al., 2009). On the other hand, numer-
ous studies also highlighted that the prompt reaction of 
hemoglobin with NO would rather configure its opposite 
role as a NO scavenger/depletor, especially in conditions 
of inflammation (reviewed in Roche et  al., 2013). The 
dispute was also fueled by divergences in the blood levels 
of S-nitrosohemoglobin reported by different laborato-
ries, possibly a result of methodological issues (Giustarini 
et al., 2004). Presently, the interpretation has eventually 
prevailed that S-nitrosohemoglobin indeed participates 
in stabilization and delivery of NO in the vascular bed, 
contributing to the regulation of vascular tone, blood flow 
and platelet aggregability (Zhang et al., 2016).
The binding of GSH to Cys-93 of Hb β chain has been 
known for more than 20  years, and was associated with 
inhibition of Hb S polymerisation, increased oxygen affin-
ity and reduced alkaline Bohr effect (Garel et  al., 1986). 
This made it an interesting candidate to combat sickle cell 
anemia; however, neither the modification of Hb by GSH 
nor by NO have translated into effective treatments for such 
disease (Head et al., 1997). In contrast,  S-glutathionylated 
Hb has been widely documented in disease states such as 
uremia or diabetes (Niwa, 2006), and it is currently believed 
to be a consequence of the oxidative stress underlying 
these diseases. At least three different types of glutath-
ionylated Hb can exist in erythrocytes: a mixed disulfide 
between GSH and normal Hb; a disulfide bond between 
GSH and the CyS-93 of metHb β-chain; and a disulfide 
bond between GSH and other cysteine residues of met-Hb 
α- and/or β-chain (Mawatari and Murakami, 2004; Regaz-
zoni et al., 2009). Rat erythrocytes treated with diamide, a 
thiol oxidizing agent, also presented Hb S-glutathionyla-
tion (Kosower et  al., 1977). Besides Cys-93, Hb glutathio-
nylation also occurs at Cys-112 in the β-chain (Metere et al., 
2014). These authors found that CO treatment of whole 
blood increases the GSH concentration in red blood cells 
cytosol, a result of significant Hb deglutathionylation. This 
process does not activate glycolytic metabolism, boosts 
the pentose phosphate pathway, increases glutathione 
reductase activity and decreases GSSG concentration, thus 
highlighting a CO-dependent redox signaling in human 
erythrocytes driven by Hb S-glutathionylation.
Caspase-3
Several years ago the antiapoptotic effect of NO was 
related to a potential inhibition of caspase-3 activation, 
through both cGMP-dependent and independent mecha-
nisms (Kim et al., 1997). It has been documented that Fas 
ligand is under the control of the NO pathway, and that 
S-nitrosation/denitrosation of caspase-3, probably linked 
to subcellular locallization, may be the mechanism by 
which this ligand controls the general process of apoptosis 
(Mannick et al., 1997, 1999). In immune-response lineage 
cells, procaspase-3 basally presents with S-nitrosation 
on its catalytic CyS-163 (Mannick et  al., 1999), and other 
caspases, such as caspase-9, could also undergo S-nitros-
ation (Mannick et al., 2001). Interestingly, Trx is involved 
in the process of S-nitrosation of caspase-3 (Mitchell and 
 Marletta, 2005) and S-nitrosation of the catalytic site Cys 
residue might be assisted by a nitrosopeptide that mimics 
the substrate configuration, thus providing an elegant 
example for a specific transnitrosation mechanism (Mitch-
ell et al., 2006).
Yin et al. (2013) investigated the effects of GSNO pre-
treatment on the S-nitrosation of Fas and subsequent 
events in the Fas pathway, revealing the correlation 
between Fas S-nitrosation and nNOS activation in rat hip-
pocampus after global cerebral ischemia. Results showed 
that GSNO pre-treatment not only facilitated the survival 
of hippocampal CA1 pyramidal neurons, but also abol-
ished the activation of pro-apoptotic caspase-3, 8 and 9, 
as well as of the pro-apoptotic protein Bid. Consistently, 
a moderate dose of GSNO would confer neuroprotection 
against ischemic injury via inhibiting FaS-dependent 
apoptosis. Fas S-nitrosation could represent the critical 
regulation hinge in such a neuroprotective mechanism. 
Actually, GSNO-generated NO S-nitrosates and inacti-
vates nNOS itself, resulting in the inhibition of endog-
enous NO production and a decrease in Fas S-nitrosation. 
This insight into GSNO-mediated neuroprotection might 
suggest therapeutic approaches for ischemic brain injury 
(Yin et al., 2013).
S-glutathionylation of caspase-3 by GSNO, or SNAP 
plus GSH, has been described by several studies (Klatt 
et al., 2000; Mitchell and Marletta, 2005). Recent observa-
tions claim that caspase-3 experiences S-glutathionylation 
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on several thiol residues and that this process is intracel-
lularly regulated by Grx, a mechanism relevant for the reg-
ulation of TNF-α-dependent endothelial cell death (Pan 
and Berk, 2006). Clearly, caspase-3 constitutes an inter-
esting model to study both types of PTMs at the cellular 
level, particularly with respect to regulation of cell death. 
However, definitive evidence establishing implications at 
whole organism level is still missing.
Myosin
NO is synthesized in skeletal muscle and its production 
increases during contractile activity. Although myosin 
is the most abundant protein in muscle, it is not known 
whether myosin is a target for NO or its derivatives. 
Nogueira et al. (2009) have shown that exercise increases 
S-nitrosation in muscle proteins, and, among contrac-
tile proteins, myosin is the principal target of exogenous 
S-nitrosothiols in both skinned skeletal muscle fibres and 
differentiated myotubes. Myosin contains 42 Cys residues, 
and different populations have been described based on 
their reactivity to sulfhydryl-specific reagents and the 
resulting changes in ATPase activity (Buttkus, 1971; Schaub 
et  al., 1975). The reaction of isolated myosin with GSNO 
results in S-nitrosation at multiple cysteines and produces 
two populations of protein-bound SNOs with different 
stabilities. The less stable population inhibits the physi-
ological Mg2+-ATPase activity without affecting the affinity 
of myosin for actin. However, myosin is neither inhibited 
nor S-nitrosated by the NO-donor diethylamine NONOate, 
indicating a requirement for transnitrosation between 
lmw. SNOs and myosin cysteine thiols rather than a direct 
reaction of myosin with NO or its auto-oxidation products. 
Interestingly, alkylation by N-ethylmaleimide of the most 
reactive thiols in myosin does not inhibit formation of a 
stable population of protein-SNOs, suggesting that these 
sites are located in regions of the protein less accessible 
than those affecting activity. This early study established 
thus a link between exercise and S-nitrosation of contrac-
tile proteins that may be important in pathophysiology of 
skeletal muscle (Buttkus, 1971).
High levels of GSNO-dependent S-nitrosation of pro-
teins from the cytoskeleton and the contractile machinery 
were recently identified under oxidative stress conditions 
(Belcastro et al., 2017). In particular, the detailed pattern of 
S-nitrosated proteins indicates that most of S-nitrosylated 
proteins are of primary relevance for the performance of 
SMC functions being often altered in vascular diseases, 
such as cell communication, cytoskeletal organization, 
morphogenesis, contraction and movement. Interestingly, 
the process involves actin and cytoskeleton dynamics at 
several key regulatory proteins, including myosin light 
polypeptide 6 (MYL6). The role of S-nitrosation in regu-
lating these proteins is largely unknown, particularly 
during oxidative stress. Each of them has been shown to 
play a role in modulating smooth muscle contraction. In 
vitro S-nitrosation of skeletal muscle myosin, for example, 
increases the force of the actomyosin interaction while 
decreasing its velocity, indicating a relaxed state (Evan-
gelista et al., 2010). MYL6 regulates light chain of myosin 
and does not bind calcium, but is anyway involved in 
muscle contraction and development of skeletal muscle 
tissue. Other proteins S-nitrosated by GSNO under oxi-
dative stress conditions include calponin-2 (CNN2) and 
transgelin (TAGLN). Together these proteins, implicated in 
Ca2+-dependent contractility and NO signaling, constitute 
a potential interactome, and discovering their behavior as 
S-nitrosated proteins may further help our understanding 
of processes such as contraction-relaxation signaling in 
SMCs, or their phenotype switching during atherosclero-
sis progression.
S-glutathionylation of myosin has an important 
impact on the protein structure, as documented by the 
lower fluorescence quantum yield of S-glutathionylated 
protein and its increased susceptibility to proteolytic 
cleavage. Myosin ATPase activity is also sensitive to modu-
lation by  S-glutathionylation, depending on GSSG redox 
balance. Thus, similar to the phosphorylation/dephos-
phorylation cycle, S-glutathionylation may represent a 
mechanism by which glutathione modulates sarcomere 
functions depending on the tissue redox state, and myosin 
may constitute the muscle redox-sensor (Passarelli et al., 
2008; Pastore and Piemonte, 2013).
α-Actin
Actin filaments are important components of the cell 
cytoskeleton, where they are often involved in the 
process of exocytosis. Actin of rabbit skeletal muscle 
has five cysteine residues at different positions, but only 
CyS-374 in the C-terminal region is exposed and impor-
tant for polymerization (Aspenström et  al., 1993). The 
same residue is a decisive site for S-nitrosation (Dalle-
Donne et  al., 2000). Recently it has been demonstrated 
that NO-induced S-nitrosation is an effective inhibitor of 
actin polymerisation (Lu et al., 2009). Actin was rapidly 
S-nitrosated in vitro by exogenous NO-generating donors 
(e.g. GSNO), and in vivo in the spinal cord of a mouse 
model of inflammatory pain. NO showed an inhibitory 
action on inhibitory synaptic transmission in the spinal 
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dorsal horn, implicating S-nitrosation in pain transmis-
sion via disinhibition of inhibitory neurons (Lu et  al., 
2009, 2011). In rat aortic SMCs stressed in vitro with a free 
radical generator (2,2′-azobis(2-amidinopropane dihydro-
chloride, AAPH), actin was S-nitrosated following expo-
sure to GSNO (Belcastro et al., 2017), but the real impact 
of this modification on SMCs functions remains to be 
elucidated.
α-Actin is also particularly sensitive to binding of 
glutathione, as shown in isolated cardiac and skeletal 
myofibrils under conditions of oxidative stress (Passarelli 
et al., 2010). S-glutathionylation of cardiac α-actin occurs 
non-enzymatically, via spontaneous oxidation of a Cys 
residue to a cysteinyl-sulfenic acid intermediary (Dalle-
Donne et  al., 2003; Johansson and Lundberg, 2007). It 
has been shown that cardiac α-actin polymerizes slower 
than the native protein, when S-glutathionylated in vitro. 
Thus, like cytoskeletal β-actin (Dalle-Donne et al., 2003; 
Fiaschi et  al., 2006) and skeletal muscle actin (Dalle-
Donne et al., 2003), even α-actin could constitute a direct 
target for oxidative modification in human heart, and its 
S-glutathionylation may represent a mechanism by which 
glutathione can modulate sarcomere function, depending 
on the redox state of the tissue.
The balance between nitrosation 
and glutathionylation of thiols: 
general considerations
How proteins become S-glutathionylated and S-nitrosated 
in vivo is not yet well established, despite continuing 
attempts to clarify this issue. The effects of S-nitrosation 
and S-glutathionylation on protein activity may be similar, 
and both modifications are reversible, but the resulting 
products, PSNOs and PSSGs, do possess different bio-
logical properties. The list of proteins undergoing these 
changes is long and not definitive; a summary of the main 
protein targets modified by S-nitrosation and/or S-glu-
tathionylation is however reported in Table 2.
The relative importance of S-nitrosation and S-glutath-
ionylation likely depends not only on the environment sur-
rounding the protein -SH groups, but also on the chemical 
nature of the intervening lmw. RSNO, which can affect the 
accessibility of the protein thionylate to either the nitro-
gen or the sulfur of the RSNO. This was shown in vitro for 
CPK, which is predominantly either S-glutathionylated or 
S-nitrosated, depending on the different species of RSNOs 
it is exposed to (Konorev et  al., 2000). CPK is reversibly 
inhibited by incubation with S-nitrosothiols (Giustarini 
et al., 2005). Loss of enzyme activity is associated with the 
depletion of 5,5′-dithiobiS-(2-nitrobenzoic acid)-accessi-
ble thiol groups, and is not due to nitric oxide release from 
RSNOs. Full enzymatic activity and protein thiol content 
are restored by incubation of the S-nitrosothiol-modified 
protein with GSH. SNAP, which contains a more steri-
cally hindered S-nitroso group than GSNO, predominantly 
modifies the CPK protein thiols via a transnitrosation 
reaction. In contrast, GSNO modifies CPK thiols predomi-
nantly by S-thionylation, while bovine serum albumin 
is nitrosated by both SNAP and GSNO. Therefore, using 
CPK as a model, the degree of S-thionylation and S-nitro-
sation appears to depend both on the protein structure 
and the chemical nature of the S-nitrosothiol, and these 
differences are likely due to both steric factors and pKa 
of the protein thiols (Konorev et al., 2000). Data suggest 
that S-glutathionylation can be a quantitatively relevant 
process likely running in parallel to S-nitrosation in some 
proteins, and that denitrosation is a largely faster process 
than deglutathionylation. In addition, it may be hypoth-
esized that stable intracellular protein RSNOs pools exist, 
likely located either in hydrophobic protein pockets inac-
cessible to GSH and other reducing agents, or in other spe-
cific cellular microenvironments (Zhang and Hogg, 2004).
Concluding remarks
In this review we have discussed the biologically relevant 
role of NO as a conveyor of signals, as well as the function 
of the endogenous nitrosating agent, GSNO, in protein 
activation and/or inactivation through S-nitrosation, 
transnitrosation, disulfide bond formation, and/or S-glu-
tathionylation. In a general perspective, these processes 
represent just one aspect of a much wider array of reac-
tions and processes related with the redox homeostasis of 
the cell, involving reactive species of oxygen and nitrogen 
but also, as increasingly recognized in recent years, of 
sulfur itself. By now, such reactive species (ROS, RNS and 
RSS) are considered as players in a complex redox signal-
ing network that interacts with protein thiol targets, acting 
as redox switches to control protein structure and func-
tion. Such a complex network has intriguingly been named 
‘reactive species interactome’ (RSI), a novel concept in cell 
biology liable to provide critical insights for the develop-
ment of prevention and treatment strategies, in what could 
be called today ‘redox medicine’ (Cortese-Krott et  al., 
2017). The RSI perspective is somehow complementary to 
(and integrated with) the redox code, and within that, to 
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the redox proteome, another concept recently introduced 
to describe how protein redox-sensitive Cys residues par-
ticipate in a wider network of redox switches, linked to the 
NAD and NADP systems and, through those, to the general 
metabolism of the cell (Jones and Sies, 2015).
Much work is still needed to more precisely define 
how the different modifications may be balanced, the 
detailed mechanisms underlying their relationships, 
and their functional implications in physiological set-
tings. The recent development of new methodologies 
(proteomics, subcellular localization studies) has moved 
knowledge some steps further, but significant analytical 
improvements are still needed in order to gain deeper 
insight into the physiological relevance of S-nitrosa-
tion and S-glutathionylation. The low, negligible levels 
of protein S-nitrosation/S-glutathionylation generally 
detectable in homeostatic conditions suggest that these 
PTM may often lack true pathophysiological roles, playing 
as mere bystanders. On the other hand, the combined 
effects of altered S-nitrosation/denitrosation and S-glu-
tathionylation/deglutathionylation on different or the 
same proteins could represent a coordinated adaptive 
response aimed to promote cell survival during short-
term oxidative/nitrosative stress. In the cardiovascular 
system, evidence is accumulating of the (patho)physi-
ological relevance of these PTMs in ensuring protection of 
Cys residues from oxidation. It will be important then to 
determine exactly which proteins and Cys residues, which 
would otherwise undergo oxidation, can be S-nitrosated 
and/or S-glutathionylated. S-Nitrosation of some proteins 
can be beneficial, whereas it can be detrimental in others, 
while S-glutathionylation of the same proteins could still 
have other effects. In the future, it will be necessary to 
understand how these processes can combine many indi-
vidual protein modifications into a global metabolic map, 
in order to fully understand the importance of reversible 
oxidative/nitrosative protein modifications. As advances 
in both the methodology and technology accelerate the 
study of S-nitrosated and S-glutathionylated proteins, the 
critical role they play in CVD is beginning to emerge. In 
perspective, the full understanding of these modifications 
may offer indications for the development of new drugs, 
and they may be as well exploited as biomarkers or predic-
tors in cardiovascular pathology.
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